Henry Fraimow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Henry Fraimow has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Constantine Tsigrelis
From the Division of Infectious Diseases, Department of Medicine, Cooper University Hospital, Camden, NJ, USA
3 shared publications- Madeline King
Philadelphia College of Pharmacy, Saint Joseph’s University , Philadelphia, Pennsylvania, USA
2 shared publications Raquel Nahra
Division of Infectious Diseases, Department of Medicine, Cooper Medical School of Rowan University, Cooper University Hospital, Camden, NJ
2 shared publications- Raquel Nahra
Division of Infectious Diseases, Department of Medicine, Cooper University Healthcare, Camden, NJ 08103, USA
2 shared publications - Valerie Jean Carabetta
Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA
2 shared publications - Christa Schorr
Cooper University Hospital, Cooper Research Institute, Critical Care, Camden, NJ, USA
1 shared publication
Latest Publications
- Open Access
- 2 January 2026
- Published by Wiley in Case Reports in Medicine
- Vol. 2026 (1) , 5210024
A Rare Presentation of Babesia‐Associated Splenic Infarction in an Immunocompetent Young Male With Mild Parasitemia
Babesiosis is a vector‐borne protozoal disease primarily transmitted by the Ixodes scapularis tick, though it can also be transmitted through blood transfusions from infected donors. The illness can be asymptomatic or present with mild flu‐like symptoms. Still, in severe cases, it can lead to disseminated intravascular coagulation and severe hemolytic anemia, sometimes necessitating management in the intensive care unit. Traditionally, severe babesiosis has been linked to individuals over 50 years old, asplenia, and those who are immunocompromised. Notably, parasitemia levels greater than 10% are also associated with severe disease. However, we report a case of a young, immunocompetent male with severe babesiosis exhibiting severe hemolytic anemia and a rare complication of splenic infarction despite a low level of parasitemia. This case emphasizes that significant clinical complications, like spontaneous splenic infarction, can arise from low parasitemia levels, underscoring the need for heightened awareness of this potential outcome.
- 2 January 2026
- Published by Wiley in Case Reports in Medicine
- Vol. 2026 (1) , 5210024
Open AccessA Rare Presentation of Babesia‐Associated Splenic Infarction in an Immunocompetent Young Male With Mild Parasitemia
Babesiosis is a vector‐borne protozoal disease primarily transmitted by the Ixodes scapularis tick, though it can also be transmitted through blood transfusions from infected donors. The illness can be asymptomatic or present with mild flu‐like symptoms. Still, in severe cases, it can lead to disseminated intravascular coagulation and severe hemolytic anemia, sometimes necessitating management in the intensive care unit. Traditionally, severe babesiosis has been linked to individuals over 50 years old, asplenia, and those who are immunocompromised. Notably, parasitemia levels greater than 10% are also associated with severe disease. However, we report a case of a young, immunocompetent male with severe babesiosis exhibiting severe hemolytic anemia and a rare complication of splenic infarction despite a low level of parasitemia. This case emphasizes that significant clinical complications, like spontaneous splenic infarction, can arise from low parasitemia levels, underscoring the need for heightened awareness of this potential outcome.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Dermatological Medicine
- Vol. 2026 (1)
Cutaneous Tuberculosis Presenting as a Chronic Dermatologic Disorder
Cutaneous tuberculosis (CTB) is a rare manifestation of extrapulmonary tuberculosis that is frequently misdiagnosed due to its diverse clinical presentation and resemblance to other dermatological conditions. Tuberculosis verrucosa cutis (TBVC), one clinical manifestation of CTB, poses a particular diagnostic challenge, as lesions are often paucibacillary, resulting in negative culture and PCR results. We present the case of a 73‐year‐old woman with a 10‐year history of recurrent skin lesions on her left hand, initially diagnosed as eczema and exacerbated by topical corticosteroid treatment. Despite repeated negative histopathological stains, mycobacterial cultures. and PCR for Mycobacterium tuberculosis, a strong positive QuantiFERON‐TB Gold test established the diagnosis. This case emphasizes the diagnostic utility of interferon‐gamma release assays (IGRAs) in paucibacillary forms of CTB. Management was complicated by adverse drug reactions (ADRs) to first‐line antituberculosis therapy (HRZE), including myalgias, fatigue, and a pruritic rash attributed to pyrazinamide and rifampin. These agents were discontinued, and the patient was transitioned to an alternative regimen, which resulted in improved tolerability and marked clinical improvement. This case highlights the diagnostic pitfalls and therapeutic challenges in managing TBVC. It underscores the importance of maintaining a high index of clinical suspicion for CTB in chronic, verrucous skin lesions, even in patients without specific TB risk factors. It also emphasizes the need for individualized treatment strategies.
- 1 January 2026
- Published by Wiley in Case Reports in Dermatological Medicine
- Vol. 2026 (1)
Open AccessCutaneous Tuberculosis Presenting as a Chronic Dermatologic Disorder
Cutaneous tuberculosis (CTB) is a rare manifestation of extrapulmonary tuberculosis that is frequently misdiagnosed due to its diverse clinical presentation and resemblance to other dermatological conditions. Tuberculosis verrucosa cutis (TBVC), one clinical manifestation of CTB, poses a particular diagnostic challenge, as lesions are often paucibacillary, resulting in negative culture and PCR results. We present the case of a 73‐year‐old woman with a 10‐year history of recurrent skin lesions on her left hand, initially diagnosed as eczema and exacerbated by topical corticosteroid treatment. Despite repeated negative histopathological stains, mycobacterial cultures. and PCR for Mycobacterium tuberculosis, a strong positive QuantiFERON‐TB Gold test established the diagnosis. This case emphasizes the diagnostic utility of interferon‐gamma release assays (IGRAs) in paucibacillary forms of CTB. Management was complicated by adverse drug reactions (ADRs) to first‐line antituberculosis therapy (HRZE), including myalgias, fatigue, and a pruritic rash attributed to pyrazinamide and rifampin. These agents were discontinued, and the patient was transitioned to an alternative regimen, which resulted in improved tolerability and marked clinical improvement. This case highlights the diagnostic pitfalls and therapeutic challenges in managing TBVC. It underscores the importance of maintaining a high index of clinical suspicion for CTB in chronic, verrucous skin lesions, even in patients without specific TB risk factors. It also emphasizes the need for individualized treatment strategies.
- Open Access
- 30 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2647
Impact of Povidone Application to Nares in Addition to Chlorhexidine Bath in Critically Ill Patients on Nosocomial Bacteremia and Central Line Blood Stream Infection
Nosocomial Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia results in a significant increase in morbidity and mortality in hospitalized patients. We aimed to analyze the impact of applying 10% povidone iodine (PI) twice daily to both nares in addition to chlorhexidine (CHG) bathing on nosocomial (MRSA) bacteremia in critically ill patients. A quality improvement study was completed with pre and post-design. The study period was from January 2018 until February 2020 and February 2021 and June 2021. The control period (from January 2018 to May 2019) consisted of CHG bathing alone, and in the intervention period, we added 10% PI to the nares of critically ill patients. Our primary outcome is rates of nosocomial MRSA bacteremia, and our secondary outcome is central line associated blood stream infection (CLABSI) and potential cost savings. There were no significant differences in rates of MRSA bacteremia in critically ill patients. Nosocomial MRSA bacteremia was significantly lower during the intervention period on medical/surgical areas (MSA). CLABSIs were significantly lower during the intervention period in critically ill patients. There were no Staphylococcus aureus CLABSIs in critical care area (CCA)during the intervention period. The intervention showed potential significant cost savings. The application of 10% povidone iodine twice a day in addition to CHG bathing resulted in a significant decrease in CLABSIs in critically ill patients and a reduction in nosocomial MRSA in the non-intervention areas. Further trials are needed to tease out individual patients who will benefit from the intervention.
- 30 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2647
Open AccessImpact of Povidone Application to Nares in Addition to Chlorhexidine Bath in Critically Ill Patients on Nosocomial Bacteremia and Central Line Blood Stream Infection
Nosocomial Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia results in a significant increase in morbidity and mortality in hospitalized patients. We aimed to analyze the impact of applying 10% povidone iodine (PI) twice daily to both nares in addition to chlorhexidine (CHG) bathing on nosocomial (MRSA) bacteremia in critically ill patients. A quality improvement study was completed with pre and post-design. The study period was from January 2018 until February 2020 and February 2021 and June 2021. The control period (from January 2018 to May 2019) consisted of CHG bathing alone, and in the intervention period, we added 10% PI to the nares of critically ill patients. Our primary outcome is rates of nosocomial MRSA bacteremia, and our secondary outcome is central line associated blood stream infection (CLABSI) and potential cost savings. There were no significant differences in rates of MRSA bacteremia in critically ill patients. Nosocomial MRSA bacteremia was significantly lower during the intervention period on medical/surgical areas (MSA). CLABSIs were significantly lower during the intervention period in critically ill patients. There were no Staphylococcus aureus CLABSIs in critical care area (CCA)during the intervention period. The intervention showed potential significant cost savings. The application of 10% povidone iodine twice a day in addition to CHG bathing resulted in a significant decrease in CLABSIs in critically ill patients and a reduction in nosocomial MRSA in the non-intervention areas. Further trials are needed to tease out individual patients who will benefit from the intervention.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
187. Risk Factors and Outcomes of Patients with Serratia Bacteremia at an Academic Medical Center
The majority of reported Serratia infective endocarditis (SIE) in recent years are healthcare-associated. At our urban institution with a high prevalence of people who inject drugs (PWID), we noted an increasing number of Serratia bacteremias (SB) and SIE over the past decade. Our study describes patient factors associated with SB and SIE. We evaluated charts of patients with SB at our institution between 2010 and 2022 to determine risk factors and clinical outcomes. There were 157 episodes of SB in 153 patients. The majority were male (57%), white (57%) with a mean age 53. The most common source of infection was catheter- line-associated infection (CLABSI) (27%), followed by primary bacteremia (19%). Twenty-six % were PWID with younger mean age (41 years). PWID had lower mortality than non-PWID (23% vs 44%, p=0.023). Sixty-nine (46%) were admitted to the intensive care unit (ICU) with significantly higher mortality associated with ICU admission (48% vs 8%, p=0.015). Echocardiograms were performed in 59% (93/157) of SB episodes and 14% had SIE (13/93). Most SIE (69%) occurred after 2017 with 89% in PWID (8/9). The most common comorbidity with SIE was injection drug use (IDU) (69%). All non-IDU SIE were CLABSI-related; 75% had hemodialysis catheters. Tricuspid valves were infected in 46%. Sixty-two % of those with SIE had septic emboli. Most SIE (69%) required ICU admission. Overall mortality was 31%. Only 2% (3/153) of patients with SB developed antibiotic resistance on therapy. Clinical worsening or failure occurred in 20% (32/157). Only 5% (7/157) had microbiologic recurrence within 30 days. 32% of discharged patients re-presented to the hospital within 30 days. Almost all deaths (92%) occurred during initial admission. Patients with SB were quite ill with a high rate of in-hospital mortality; over half of the patients had antibiotic exposures prior to developing SB or presented within 90 days of a prior hospitalization. The majority of SB were line-associated, including all episodes of non-IDU SIE. IDU was the second most common comorbidity and PWID with SB had a higher rate of SIE, with most IDU-associated SIE diagnosed after 2017. This aligns with other recent studies documenting the increased prevalence of SB, especially in PWID. Madeline King, PharmD, La Jolla: Advisor/Consultant|Shionogi: Advisor/Consultant
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access187. Risk Factors and Outcomes of Patients with Serratia Bacteremia at an Academic Medical Center
The majority of reported Serratia infective endocarditis (SIE) in recent years are healthcare-associated. At our urban institution with a high prevalence of people who inject drugs (PWID), we noted an increasing number of Serratia bacteremias (SB) and SIE over the past decade. Our study describes patient factors associated with SB and SIE. We evaluated charts of patients with SB at our institution between 2010 and 2022 to determine risk factors and clinical outcomes. There were 157 episodes of SB in 153 patients. The majority were male (57%), white (57%) with a mean age 53. The most common source of infection was catheter- line-associated infection (CLABSI) (27%), followed by primary bacteremia (19%). Twenty-six % were PWID with younger mean age (41 years). PWID had lower mortality than non-PWID (23% vs 44%, p=0.023). Sixty-nine (46%) were admitted to the intensive care unit (ICU) with significantly higher mortality associated with ICU admission (48% vs 8%, p=0.015). Echocardiograms were performed in 59% (93/157) of SB episodes and 14% had SIE (13/93). Most SIE (69%) occurred after 2017 with 89% in PWID (8/9). The most common comorbidity with SIE was injection drug use (IDU) (69%). All non-IDU SIE were CLABSI-related; 75% had hemodialysis catheters. Tricuspid valves were infected in 46%. Sixty-two % of those with SIE had septic emboli. Most SIE (69%) required ICU admission. Overall mortality was 31%. Only 2% (3/153) of patients with SB developed antibiotic resistance on therapy. Clinical worsening or failure occurred in 20% (32/157). Only 5% (7/157) had microbiologic recurrence within 30 days. 32% of discharged patients re-presented to the hospital within 30 days. Almost all deaths (92%) occurred during initial admission. Patients with SB were quite ill with a high rate of in-hospital mortality; over half of the patients had antibiotic exposures prior to developing SB or presented within 90 days of a prior hospitalization. The majority of SB were line-associated, including all episodes of non-IDU SIE. IDU was the second most common comorbidity and PWID with SB had a higher rate of SIE, with most IDU-associated SIE diagnosed after 2017. This aligns with other recent studies documenting the increased prevalence of SB, especially in PWID. Madeline King, PharmD, La Jolla: Advisor/Consultant|Shionogi: Advisor/Consultant
- Open Access
- 23 September 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (10) , 1298
Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates
For decades, the spread of multidrug-resistant (MDR) Acinetobacter baumannii has been rampant in critically ill, hospitalized patients. Traditional antibiotic therapies against this pathogen have been failing, leading to rising concerns over management options for patients. Two new antibiotics, eravacycline and omadacycline, were introduced to the market and have shown promising results in the treatment of Gram-negative infections. Since these drugs are newly available, there is limited in vitro data about their effectiveness against MDR A. baumannii or even susceptible strains. Here, we examined the effectiveness of 22 standard-of-care antibiotics, eravacycline, and omadacycline against susceptible and extensively drug-resistant (XDR) A. baumannii patient isolates from Cooper University Hospital. Furthermore, we examined selected combinations of eravacycline or omadacycline with other antibiotics against an XDR strain. We demonstrated that this collection of strains is largely resistant to monotherapies of carbapenems, fluoroquinolones, folate pathway antagonists, cephalosporins, and most tetracyclines. While clinical breakpoint data are not available for eravacycline or omadacycline, based on minimum inhibitory concentrations, eravacycline was highly effective against these strains. The aminoglycoside amikacin alone and in combination with eravacycline or omadacycline yielded the most promising results. Our comprehensive characterization offers direction in the treatment of this deadly infection in hospitalized patients.
- 23 September 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (10) , 1298
Open AccessEvaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates
For decades, the spread of multidrug-resistant (MDR) Acinetobacter baumannii has been rampant in critically ill, hospitalized patients. Traditional antibiotic therapies against this pathogen have been failing, leading to rising concerns over management options for patients. Two new antibiotics, eravacycline and omadacycline, were introduced to the market and have shown promising results in the treatment of Gram-negative infections. Since these drugs are newly available, there is limited in vitro data about their effectiveness against MDR A. baumannii or even susceptible strains. Here, we examined the effectiveness of 22 standard-of-care antibiotics, eravacycline, and omadacycline against susceptible and extensively drug-resistant (XDR) A. baumannii patient isolates from Cooper University Hospital. Furthermore, we examined selected combinations of eravacycline or omadacycline with other antibiotics against an XDR strain. We demonstrated that this collection of strains is largely resistant to monotherapies of carbapenems, fluoroquinolones, folate pathway antagonists, cephalosporins, and most tetracyclines. While clinical breakpoint data are not available for eravacycline or omadacycline, based on minimum inhibitory concentrations, eravacycline was highly effective against these strains. The aminoglycoside amikacin alone and in combination with eravacycline or omadacycline yielded the most promising results. Our comprehensive characterization offers direction in the treatment of this deadly infection in hospitalized patients.
- Open Access
- 3 May 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (5) , 614
Evaluating the Effectiveness of Hospital Antiseptics on Multidrug-Resistant Acinetobacter baumannii: Understanding the Relationship between Microbicide and Antibiotic Resistance
Acinetobacter baumannii hospital infections are difficult to treat due to the rapid emergence of multidrug-resistant (MDR) strains. In addition, A. baumannii can survive in numerous adverse environments, including in the presence of common hospital antiseptics. We hypothesized that in addition to accumulating drug resistance determinants, MDR A. baumannii strains also accumulate mutations that allow for greater microbicide tolerance when compared to pan-susceptible (PS) strains. To test this hypothesis, we compared the survival of five MDR and five PS patient isolates when exposed to bleach, ethanol, quaternary ammonium compounds, chlorhexidine gluconate, and povidone. We evaluated bacteria in a free-living planktonic state and under biofilm conditions. Each disinfectant eliminated 99.9% of planktonic bacteria, but this was not the case for bacterial biofilms. Next, we characterized strains for the presence of the known microbicide-resistance genes cepA, qacEΔ1, qacE, and qacA. MDR strains did not survive more than PS strains in the presence of microbicides, but microbicide-resistant strains had higher survival rates under some conditions. Interestingly, the PS strains were more likely to possess microbicide-resistance genes. Microbicide resistance remains an important topic in healthcare and may be independent of antimicrobial resistance. Hospitals should consider stricter isolation precautions that take pan-susceptible strains into account.
- 3 May 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (5) , 614
Open AccessEvaluating the Effectiveness of Hospital Antiseptics on Multidrug-Resistant Acinetobacter baumannii: Understanding the Relationship between Microbicide and Antibiotic Resistance
Acinetobacter baumannii hospital infections are difficult to treat due to the rapid emergence of multidrug-resistant (MDR) strains. In addition, A. baumannii can survive in numerous adverse environments, including in the presence of common hospital antiseptics. We hypothesized that in addition to accumulating drug resistance determinants, MDR A. baumannii strains also accumulate mutations that allow for greater microbicide tolerance when compared to pan-susceptible (PS) strains. To test this hypothesis, we compared the survival of five MDR and five PS patient isolates when exposed to bleach, ethanol, quaternary ammonium compounds, chlorhexidine gluconate, and povidone. We evaluated bacteria in a free-living planktonic state and under biofilm conditions. Each disinfectant eliminated 99.9% of planktonic bacteria, but this was not the case for bacterial biofilms. Next, we characterized strains for the presence of the known microbicide-resistance genes cepA, qacEΔ1, qacE, and qacA. MDR strains did not survive more than PS strains in the presence of microbicides, but microbicide-resistant strains had higher survival rates under some conditions. Interestingly, the PS strains were more likely to possess microbicide-resistance genes. Microbicide resistance remains an important topic in healthcare and may be independent of antimicrobial resistance. Hospitals should consider stricter isolation precautions that take pan-susceptible strains into account.
- Open Access
- 1 November 2021
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (Supplement) , S719-S720
1262. Salvage Therapies for Carbapenem Resistant Acinetobacter baumanii Outbreak in a Tertiary Care Center
The 2019 Antimicrobial Resistance Threat Report cites carbapenem-resistant Acinetobacter baumanii (CRAB) as an urgent threat causing > 700 deaths per year.1 Acinetobacter is unique in its ability to acquire resistance determinants and pan-resistant strains have been previously reported.2 It has the propensity to cause outbreaks, especially in critically ill populations due to its ability to survive on surfaces.3,4 In 2018, our hospital experienced a large CRAB outbreak. All strains were multi-drug resistant and most were identified by the Centers for Disease Control as containing OXA-23 ß-lactamase. Standard of care (SOC) was limited to agents with high toxicity potential, and thus we explored emerging therapies. In collaboration with Shionogi Inc., we obtained compassionate use cefiderocol as salvage therapy in patients failing SOC. We present our experience utilizing various treatments for CRAB infections during a hospital outbreak. We performed a retrospective chart review in adult patients with a CRAB infection treated with either cefiderocol or SOC for greater than 2 days from 08/2017 - 01/2020. SOC included use > 1 of the following: tigecycline, meropenem, polymyxins, amikacin, or eravacycline. At the time of our outbreak, we developed an institutional algorithm delineating which therapy to initiate depending on infection type. Demographic characteristics, illness severity scores, type of infection, and patient outcomes were evaluated. The median age [IQR] for the cefiderocol group was 57.5 [42 to 69] versus 60 [50 to 65] in the SOC group. Illness severity scores were lower in the cefiderocol group: SOFA median value [IQR] 3.5 [1.5 - 5] versus 5 [2 - 7] and CCI median value [IQR] was 3 [2.00 -3.00] versus 3 [2 -5] (Table 1). In hospital mortality was similar in both groups with the cefiderocol group having 50% in hospital mortality versus 42.2% in the SOC group. 28-day mortality was 62.6% in the cefiderocol group versus 42.4% in the SOC group (Table 2). Cefiderocol may be a viable option for salvage therapy for CRAB infection. Our cohort illustrated similar outcomes as standard therapy. This study is limited by a small sample size receiving cefiderocol and the significant delay associated with obtaining cefiderocol at the time. Lucia Rose, PharmD, Allergan (Speaker’s Bureau)Paratek (Employee) Madeline king, PharmD, Tetraphase (Speaker’s Bureau) Henry Fraimow, MD, Astellas pharma (Grant/Research Support)Merck (Grant/Research Support)Shionogi (Consultant, Grant/Research Support, Scientific Research Study Investigator) Dana D. Byrne, MD, MSc, Merck (Employee)
- 1 November 2021
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (Supplement) , S719-S720
Open Access1262. Salvage Therapies for Carbapenem Resistant Acinetobacter baumanii Outbreak in a Tertiary Care Center
The 2019 Antimicrobial Resistance Threat Report cites carbapenem-resistant Acinetobacter baumanii (CRAB) as an urgent threat causing > 700 deaths per year.1 Acinetobacter is unique in its ability to acquire resistance determinants and pan-resistant strains have been previously reported.2 It has the propensity to cause outbreaks, especially in critically ill populations due to its ability to survive on surfaces.3,4 In 2018, our hospital experienced a large CRAB outbreak. All strains were multi-drug resistant and most were identified by the Centers for Disease Control as containing OXA-23 ß-lactamase. Standard of care (SOC) was limited to agents with high toxicity potential, and thus we explored emerging therapies. In collaboration with Shionogi Inc., we obtained compassionate use cefiderocol as salvage therapy in patients failing SOC. We present our experience utilizing various treatments for CRAB infections during a hospital outbreak. We performed a retrospective chart review in adult patients with a CRAB infection treated with either cefiderocol or SOC for greater than 2 days from 08/2017 - 01/2020. SOC included use > 1 of the following: tigecycline, meropenem, polymyxins, amikacin, or eravacycline. At the time of our outbreak, we developed an institutional algorithm delineating which therapy to initiate depending on infection type. Demographic characteristics, illness severity scores, type of infection, and patient outcomes were evaluated. The median age [IQR] for the cefiderocol group was 57.5 [42 to 69] versus 60 [50 to 65] in the SOC group. Illness severity scores were lower in the cefiderocol group: SOFA median value [IQR] 3.5 [1.5 - 5] versus 5 [2 - 7] and CCI median value [IQR] was 3 [2.00 -3.00] versus 3 [2 -5] (Table 1). In hospital mortality was similar in both groups with the cefiderocol group having 50% in hospital mortality versus 42.2% in the SOC group. 28-day mortality was 62.6% in the cefiderocol group versus 42.4% in the SOC group (Table 2). Cefiderocol may be a viable option for salvage therapy for CRAB infection. Our cohort illustrated similar outcomes as standard therapy. This study is limited by a small sample size receiving cefiderocol and the significant delay associated with obtaining cefiderocol at the time. Lucia Rose, PharmD, Allergan (Speaker’s Bureau)Paratek (Employee) Madeline king, PharmD, Tetraphase (Speaker’s Bureau) Henry Fraimow, MD, Astellas pharma (Grant/Research Support)Merck (Grant/Research Support)Shionogi (Consultant, Grant/Research Support, Scientific Research Study Investigator) Dana D. Byrne, MD, MSc, Merck (Employee)
- 22 January 2015
- Published by Taylor & Francis in Infectious Diseases
- Vol. 47 (4) , 197-202
Risk ofClostridium difficileinfection in intensive care unit patients with sepsis exposed to metronidazole
Antimicrobial agents used to treat Clostridium difficile infection (CDI), such as metronidazole and vancomycin, have been used during antibiotic treatment of other infections to try to prevent the development of CDI. We evaluated the hypothesis that intensive care unit (ICU) patients who receive metronidazole as part of an antibiotic treatment regimen for sepsis have a lower risk of subsequently developing CDI. This was a nested case-control study in a cohort of ICU patients who received antibiotic therapy for sepsis. A total of 10 012 patients aged ≥ 18 years were admitted to the Cooper University Hospital medical/surgical ICU from 1/1/2003 to 12/31/2008. After applying inclusion criteria including having received antibiotic therapy for sepsis and subsequently having developed CDI, 67 cases were identified. The cases were matched for age, gender, date of ICU admission, and hospital length of stay to 67 controls that also received antibiotic therapy for sepsis but did not subsequently develop CDI. In the multivariate analysis, there was no association between metronidazole exposure and the risk of CDI (odds ratio (OR) = 0.57; p = 0.23). The only significant associations on multivariate analysis were antifungal therapy (OR = 0.30; p = 0.02) and aminoglycoside and/or colistin therapy (OR = 0.17; p = 0.02). No association was found between metronidazole use and subsequent CDI in ICU patients who received antibiotic therapy for sepsis.
- 22 January 2015
- Published by Taylor & Francis in Infectious Diseases
- Vol. 47 (4) , 197-202
Risk ofClostridium difficileinfection in intensive care unit patients with sepsis exposed to metronidazole
Antimicrobial agents used to treat Clostridium difficile infection (CDI), such as metronidazole and vancomycin, have been used during antibiotic treatment of other infections to try to prevent the development of CDI. We evaluated the hypothesis that intensive care unit (ICU) patients who receive metronidazole as part of an antibiotic treatment regimen for sepsis have a lower risk of subsequently developing CDI. This was a nested case-control study in a cohort of ICU patients who received antibiotic therapy for sepsis. A total of 10 012 patients aged ≥ 18 years were admitted to the Cooper University Hospital medical/surgical ICU from 1/1/2003 to 12/31/2008. After applying inclusion criteria including having received antibiotic therapy for sepsis and subsequently having developed CDI, 67 cases were identified. The cases were matched for age, gender, date of ICU admission, and hospital length of stay to 67 controls that also received antibiotic therapy for sepsis but did not subsequently develop CDI. In the multivariate analysis, there was no association between metronidazole exposure and the risk of CDI (odds ratio (OR) = 0.57; p = 0.23). The only significant associations on multivariate analysis were antifungal therapy (OR = 0.30; p = 0.02) and aminoglycoside and/or colistin therapy (OR = 0.17; p = 0.02). No association was found between metronidazole use and subsequent CDI in ICU patients who received antibiotic therapy for sepsis.
- 1 July 2014
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 28 (5) , 1314.e5-1314.e10
Salmonella Aortitis Treated with Endovascular Aortic Repair
- 1 July 2014
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 28 (5) , 1314.e5-1314.e10
Salmonella Aortitis Treated with Endovascular Aortic Repair
- 1 October 2013
- Published by Elsevier in Critical Care Clinics
- Vol. 29 (4) , 895-921
Resistant Gram-Negative Infections
- 1 October 2013
- Published by Elsevier in Critical Care Clinics
- Vol. 29 (4) , 895-921
Resistant Gram-Negative Infections